van Steen, Cécile http://orcid.org/0000-0002-8872-2678
Celico, Lorenzo
Spaepen, Erik
Hagenacker, Tim http://orcid.org/0000-0002-3631-3450
Meuth, Sven G. http://orcid.org/0000-0003-2571-3501
Ruck, Tobias http://orcid.org/0000-0001-6332-8650
Smith, A. Gordon http://orcid.org/0009-0008-7909-9395
Bodicoat, Danielle H. http://orcid.org/0000-0002-2184-4865
de Francesco, Maria http://orcid.org/0000-0002-7118-5845
Iannazzo, Sergio http://orcid.org/0000-0003-3226-5954
Article History
Received: 26 February 2024
Accepted: 22 March 2024
First Online: 20 April 2024
Declarations
:
: Cécile van Steen and Sergio Iannazzo were employees of argenx BV, who manufacture efgartigimod, when the manuscript was completed. Cécile van Steen has since changed affiliation to Biogen Netherlands BV. Celico, Spaepen, Bodicoat and de Francesco have received research funding from argenx BV. Hagenacker has received research support from Biogen, Novartis GeneTherapies, Roche and Sanofi Genzyme, speakers and consultant honoraria from Biogen, Hormosan, Roche, Alexion, Novartis, Roche, Sanofi-Genzyme, Alnylam and Argenx. Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer HealthCare, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. Tobias Ruck reports grants from German Ministry of Education, Science, Research and Technology; grants and personal fees from Sanofi-Genzyme; personal fees from Biogen and Novartis; personal fees and non-financial support from Merck Serono; personal fees from Roche, Teva, Alexion, argenx BV, UCB, and BMS. A Gordon Smith has received research support from Alexion, argenx BV, Janssen, Seismic, and UCB.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, therefore IRB approval was not required. In this indirect treatment comparison, no real-life patients were included and IRB approval was therefore not required.